Cargando…
Discovery of Pharmaceutical Composition for Prevention and Treatment in Patient-Derived Metastatic Medullary Thyroid Carcinoma Model
Medullary thyroid carcinoma (MTC) is a well-known neuroendocrine carcinoma, derived from C cells of the thyroid gland. Additionally, MTC is an uncommon aggressive carcinoma that metastasizes to lymph nodes, bones, lungs and liver. For MTC, the 10-year general survival ratio of patients with localize...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405678/ https://www.ncbi.nlm.nih.gov/pubmed/36009450 http://dx.doi.org/10.3390/biomedicines10081901 |
_version_ | 1784773936725098496 |
---|---|
author | Yun, Hyeok-Jun Lim, Jin-Hong Kim, Sang-Yong Kim, Seok-Mo Park, Ki-Cheong |
author_facet | Yun, Hyeok-Jun Lim, Jin-Hong Kim, Sang-Yong Kim, Seok-Mo Park, Ki-Cheong |
author_sort | Yun, Hyeok-Jun |
collection | PubMed |
description | Medullary thyroid carcinoma (MTC) is a well-known neuroendocrine carcinoma, derived from C cells of the thyroid gland. Additionally, MTC is an uncommon aggressive carcinoma that metastasizes to lymph nodes, bones, lungs and liver. For MTC, the 10-year general survival ratio of patients with localized disease is about 95%, whereas that of patients with local phase disorder is around 75%. Only 20% of patients with distant metastasis to lung at diagnosis survive 10 years, which is notably lower than survival for well-differentiated thyroid carcinoma (WDTC). The management of MTC with distant metastasis to lung could be re-surgery or chemotherapy. In this research, we planned to assess the in vitro and in vivo combinational anticancer effect of a novel combination of low-dose cisplatin and sorafenib in patient-derived MTC. The patient-derived MTC cell lines YUMC-M1, M2, and M3 were isolated and treated with a combination of cisplatin and sorafenib or either agent alone. Cisplatin and sorafenib acted in combination to forward tumor restraint compared with each agent administered alone at a low dose. Therefore, a combination of cisplatin and sorafenib could be a new therapeutic approach for MTC. |
format | Online Article Text |
id | pubmed-9405678 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94056782022-08-26 Discovery of Pharmaceutical Composition for Prevention and Treatment in Patient-Derived Metastatic Medullary Thyroid Carcinoma Model Yun, Hyeok-Jun Lim, Jin-Hong Kim, Sang-Yong Kim, Seok-Mo Park, Ki-Cheong Biomedicines Article Medullary thyroid carcinoma (MTC) is a well-known neuroendocrine carcinoma, derived from C cells of the thyroid gland. Additionally, MTC is an uncommon aggressive carcinoma that metastasizes to lymph nodes, bones, lungs and liver. For MTC, the 10-year general survival ratio of patients with localized disease is about 95%, whereas that of patients with local phase disorder is around 75%. Only 20% of patients with distant metastasis to lung at diagnosis survive 10 years, which is notably lower than survival for well-differentiated thyroid carcinoma (WDTC). The management of MTC with distant metastasis to lung could be re-surgery or chemotherapy. In this research, we planned to assess the in vitro and in vivo combinational anticancer effect of a novel combination of low-dose cisplatin and sorafenib in patient-derived MTC. The patient-derived MTC cell lines YUMC-M1, M2, and M3 were isolated and treated with a combination of cisplatin and sorafenib or either agent alone. Cisplatin and sorafenib acted in combination to forward tumor restraint compared with each agent administered alone at a low dose. Therefore, a combination of cisplatin and sorafenib could be a new therapeutic approach for MTC. MDPI 2022-08-05 /pmc/articles/PMC9405678/ /pubmed/36009450 http://dx.doi.org/10.3390/biomedicines10081901 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Yun, Hyeok-Jun Lim, Jin-Hong Kim, Sang-Yong Kim, Seok-Mo Park, Ki-Cheong Discovery of Pharmaceutical Composition for Prevention and Treatment in Patient-Derived Metastatic Medullary Thyroid Carcinoma Model |
title | Discovery of Pharmaceutical Composition for Prevention and Treatment in Patient-Derived Metastatic Medullary Thyroid Carcinoma Model |
title_full | Discovery of Pharmaceutical Composition for Prevention and Treatment in Patient-Derived Metastatic Medullary Thyroid Carcinoma Model |
title_fullStr | Discovery of Pharmaceutical Composition for Prevention and Treatment in Patient-Derived Metastatic Medullary Thyroid Carcinoma Model |
title_full_unstemmed | Discovery of Pharmaceutical Composition for Prevention and Treatment in Patient-Derived Metastatic Medullary Thyroid Carcinoma Model |
title_short | Discovery of Pharmaceutical Composition for Prevention and Treatment in Patient-Derived Metastatic Medullary Thyroid Carcinoma Model |
title_sort | discovery of pharmaceutical composition for prevention and treatment in patient-derived metastatic medullary thyroid carcinoma model |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405678/ https://www.ncbi.nlm.nih.gov/pubmed/36009450 http://dx.doi.org/10.3390/biomedicines10081901 |
work_keys_str_mv | AT yunhyeokjun discoveryofpharmaceuticalcompositionforpreventionandtreatmentinpatientderivedmetastaticmedullarythyroidcarcinomamodel AT limjinhong discoveryofpharmaceuticalcompositionforpreventionandtreatmentinpatientderivedmetastaticmedullarythyroidcarcinomamodel AT kimsangyong discoveryofpharmaceuticalcompositionforpreventionandtreatmentinpatientderivedmetastaticmedullarythyroidcarcinomamodel AT kimseokmo discoveryofpharmaceuticalcompositionforpreventionandtreatmentinpatientderivedmetastaticmedullarythyroidcarcinomamodel AT parkkicheong discoveryofpharmaceuticalcompositionforpreventionandtreatmentinpatientderivedmetastaticmedullarythyroidcarcinomamodel |